Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 26.97%.

  • Axsome Therapeutics' EBITDA Margin rose 328100.0% to 26.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.85%, marking a year-over-year increase of 526300.0%. This contributed to the annual value of 72.74% for FY2024, which is 129300.0% up from last year.
  • As of Q3 2025, Axsome Therapeutics' EBITDA Margin stood at 26.97%, which was up 328100.0% from 24.47% recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' EBITDA Margin peaked at 6.74% during Q1 2023, and registered a low of 444.23% during Q2 2022.
  • For the 4-year period, Axsome Therapeutics' EBITDA Margin averaged around 123.66%, with its median value being 89.62% (2024).
  • In the last 5 years, Axsome Therapeutics' EBITDA Margin soared by 3049200bps in 2023 and then tumbled by -829600bps in 2024.
  • Over the past 4 years, Axsome Therapeutics' EBITDA Margin (Quarter) stood at 245.86% in 2022, then surged by 44bps to 137.39% in 2023, then surged by 55bps to 61.14% in 2024, then skyrocketed by 56bps to 26.97% in 2025.
  • Its EBITDA Margin stands at 26.97% for Q3 2025, versus 24.47% for Q2 2025 and 46.91% for Q1 2025.